Skip to content
Tuesday 11 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,844.19
-0.17%
DAX
26,391.42
+0.26%
CAC 40
8,714.94
-0.13%
STOXX 50
6,551.22
+0.24%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Wednesday 25 August 2021 10:23 am  |  Updated:  Friday 12 November 2021 10:01 am

Covid protection from two vaccine doses fades after six months

By: Lily Russell-Jones

Add as a preferred source on Google
Vaccine doses delivered
Protection against Covid-19 from two vaccine doses starts to fade within six months according to UK researchers.

Protection against Covid offered by two doses of the Pfizer and the AstraZeneca vaccines begins to fade within six months underscoring the need for booster jabs according to UK researchers.

Scientists behind the Zoe Covid Study app said that effectiveness of the Pfizer vaccine against infection fell from 88 per cent to 74 per cent five to six months after the second jab.

Likewise, protection from the AstraZeneca vaccine decreased from 77 per cent to 67 per cent within four to five months of receiving the second dose.

Commenting on the study, Professor Finn of the University of Bristol, told the BBC: “I think the Zoe study, and a couple of other studies we recently had, do show the beginnings of a drop off of protection against asymptomatic or mildly symptomatic disease.

“But other studies are showing maintenance of good protection against serious illness and hospitalisation. So that’s encouraging actually that people who’ve had two doses are still very much well protected against serious illness, which is our main objective.”

The news comes after the government announced cautious plans to issue booster shots to the most vulnerable groups over the Winter to protect against Covid-19 and its future variants.

A study from the University’s of Glasgow and Birmingham recently found that 40 per cent of people who are immunosuppressed generated a lower antibody response with 11 per cent registering an “undetectable” amount of anti bodies within four weeks of being double jabbed.

Professor Finn, who is Chairman of the WHO’s European committee on immunisation, also said that the elderly would be good candidates for a third dose of the vaccine.

On Tuesday the government announced that a further 174 people had died within 28 days of testing positive for Covid-19, the highest reported daily death toll since March 12.

Read more: Third dose of Pfizer vaccine: Covid-19 booster shots ‘are working’

Read more

Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • Coronavirus
  • Covid-19 a year on
  • Vaccine

Trending Articles

  • Five-star Mayfair hotel hit with HMRC winding-up petition

  • Nottingham Forest owner Marinakis sues Crystal Palace for defamation

  • Back to basics: Sainsbury’s gradual retreat from the British high street

  • Hargreaves Lansdown orders staff back to office

  • As it happened: Intel, Arm shares slide; Oil climbs higher

More from Morning Wire

  • Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

    Business Wire
  • ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

    Business Wire
  • Prothena Reports Second Quarter 2026 Financial Results and Business Highlights

    Business Wire
  • Astrazeneca share price tumbles on $400bn megamerger talks

    Investing
    Astrazeneca headquarters with logo, reflecting commitment to reduce US medicine prices after Trump administration pressure
  • Astrazeneca explores $400bn megadeal with US rival 

    Markets
    AstraZeneca building exterior with logo, glass facade, UK flag, and wildflowers in foreground.
  • Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026

    Business Wire
  • Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION

    Business Wire
  • Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook